Targets › KDR
32 programs from 29 companies in 513 trials: 372 Phase 2, 65 Phase 1, 64 Phase 3, 12 Phase 4; Oncology, Other, Respiratory; next expected readout Dec 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. (UniProt, P35968)
Open in Phaseline: the race on KDR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chia Tai Tianqing Pharmaceutical Group | Catequentinib Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor | KDR, FLT4, KIT, PDGFRB | Phase 4 | Medullary Thyroid Cancer; Advanced Hepatocellular Carcinoma (HCC); Metastatic Colorectal Cancer; Hepatocellular Carcinoma … | Dec 2026 |
| Exelixis | Cabozantinib (XL184) Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor | KDR, MET | Phase 4 | Medullary Thyroid Cancer; Hepatocellular Carcinoma; Metastatic Prostate Cancer; Renal Cell Carcinoma … | Jan 2027 |
| Takeda | Fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 4 | Colorectal Cancer | Oct 2027 |
| Eli Lilly | Ramucirumab (LY3009806) Vascular endothelial growth factor receptor 2 inhibitor | KDR | Phase 3 | Metastatic Non-Small Cell Lung Cancer; Biliary Tract Cancer; Neoplasms; Recurrent Lung Non-Small Cell Carcinoma … | Dec 2026 |
| National Cancer Institute (NCI) | Cabozantinib S-malate Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor | KDR, MET | Phase 3 | Functioning Pancreatic Neuroendocrine Tumor; Clear Cell Renal Cell Carcinoma; Advanced Bladder Urothelial Carcinoma; Differentiated Thyroid Gland Carcinoma … | Dec 2026 |
| Shanghai Junshi Bioscience Co., Ltd. | Lenvatinib mesylate Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Advanced Hepatocellular Carcinoma (HCC); Intrahepatic Cholangiocarcinoma | Dec 2026 |
| Ocular Therapeutix | Axitinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Neovascular Age-related Macular Degeneration; Non-Proliferative Diabetic Retinopathy; Neovascular Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD) … | Jan 2027 |
| University Hospital, Bordeaux | PD-1/PD-L1 ICI + VEGFR-TKI combination PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor | PDCD1, CD274, KDR, FLT1, FLT4 | Phase 3 | Metastatic Renal Cell Carcinoma | Jan 2027 |
| Merck & Co. (MSD) | Lenvatinib (MK-7902) Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Carcinoma, Renal Cell; Solid Tumors; Neoplasm Malignant; Esophageal Squamous Cell Carcinoma … | Feb 2027 |
| Advenchen Laboratories | Catequentinib (AL3818) Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor | KDR, FLT4, KIT, PDGFRB | Phase 3 | Alveolar Soft Part Sarcoma | Dec 2027 |
| AO GENERIUM | GNR-139 Aflibercept biosimilar; VEGF-A and PlGF antagonist; binds VEGFR1 and VEGFR2 | FLT1, KDR, FLT4 | Phase 3 | nAMD | May 2028 |
| Hutchmed | fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Advanced Endometrial Cancer; Advanced Renal Cell Carcinoma | Jan 2029 |
| Alliance for Clinical Trials in Oncology | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 3 | Clear Cell Renal Cell Carcinoma | Nov 2037 |
| Jiangsu HengRui Medicine | Rivoceranib Mesylate Vascular endothelial growth factor receptor 2 inhibitor | KDR | Phase 3 | Gastric Cancer; Hepatocellular Carcinoma; Hepatocellular Carcinoma (HCC); BCLC Stage C Hepatocellular Carcinoma … | – |
| Avalyn Pharma | Nintedanib (AP02) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer … | Dec 2026 |
| Henan Cancer Hospital | Lenvatinib Mesylate Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 2 | Effectiveness | Dec 2026 |
| Chipscreen Biosciences | Ibcasertib Serine/threonine-protein kinase Aurora-B inhibitor; Vascular endothelial growth factor receptor inhibitor | AURKB, FLT1, FLT4, KDR | Phase 2 | Pancreatic Ductal Adenocarcinoma | Feb 2027 |
| M.D. Anderson Cancer Center | Cabozantinib S-malate Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor | KDR, MET | Phase 2 | Malignant Neoplasms of Urinary Tract; Locally Advanced Osteosarcoma; Brain Metastases; Advanced Breast Carcinoma … | Apr 2027 |
| City of Hope Medical Center | Lenvatinib Mesylate Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 2 | Advanced Pancreatic Ductal Adenocarcinoma; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 | Apr 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Anlotinib Hydrochloride multi-target tyrosine kinase inhibitor (VEGFR, PDGFR, FGFR inhibitor) | KDR, PDGFRA, FLT4 | Phase 2 | Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer | Jun 2027 |
| Jinling Hospital, China | PD-1/PD-L1 ICI + VEGFR-TKI PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor | PDCD1, CD274, KDR | Phase 2 | Renal Cell Carcinoma (RCC) | Aug 2027 |
| Mannkind | Nintedanib (MNKD-201) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis | Dec 2027 |
| GrandPharma (China) | Rivoceranib Vascular endothelial growth factor receptor 2 inhibitor | KDR | Phase 2 | HCC | Dec 2027 |
| Criterium | Fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 2 | Colorectal Cancer; Metastatic Oesogastric Adenocarcinoma; Gastric Cancer; Hepatocellular Carcinoma … | Dec 2027 |
| Hutchmed | Surufatinib Fibroblast growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | FGFR1, FLT1, FLT4, KDR | Phase 2 | Metastatic Pancreatic Cancer; Neuroendocrine Tumors; Pancreatic Cancer, Adult; Intrahepatic Cholangiocarcinoma … | May 2028 |
| M.D. Anderson Cancer Center | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 2 | Renal Cell Carcinoma | Nov 2028 |
| Guangzhou Virotech Pharmaceutical | Rivoceranib Vascular endothelial growth factor receptor 2 inhibitor | KDR | Phase 2 | HCC; Hepatocellular Carcinoma; Advanced Breast Cancer; Acral Melanoma … | Dec 2028 |
| University of Florida | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 1 | Bile Duct Cancer | Dec 2026 |
| Betta Pharmaceuticals | X-82 Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 1 | DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib … | Jan 2027 |
| Ottimo Pharma | OTP-01 Dual paratopic PD-1/VEGFR2 antibody | PDCD1, KDR | Phase 1 | Advanced Solid Tumors | Dec 2028 |
| National Cancer Institute (NCI) | Tivozanib (AV-951) Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 1 | Cholangiocarcinoma | Dec 2028 |
| Sun Yat-sen University | KDR2-2 suspension eyedrop VEGFR2 inhibitor with moderate PDGFRβ inhibition | KDR, PDGFRB | Phase 1 | Neovascular Glaucoma | – |
Hepatocellular Carcinoma (23) Gastric Cancer (12) Colorectal Cancer (12) Metastatic Renal Cell Carcinoma (10) HCC (8) Hepatocellular Carcinoma Non-resectable (8) Breast Cancer (8) Renal Cell Carcinoma (7) Intrahepatic Cholangiocarcinoma (7) Clear Cell Renal Cell Carcinoma (7) Hepatocellular Carcinoma (HCC) (7) Non Small Cell Lung Cancer (7)
small molecule (16), mixed (15), antibody (1)
National Cancer Institute (NCI) (2) M.D. Anderson Cancer Center (2) Hutchmed (2) Exelixis (1) Merck & Co. (MSD) (1) University Hospital, Bordeaux (1) Jiangsu HengRui Medicine (1) Chia Tai Tianqing Pharmaceutical Group (1) Takeda (1) Tianjin Medical University Cancer Institute and Hospital (1) AO GENERIUM (1) Chipscreen Biosciences (1) Avalyn Pharma (1) Alliance for Clinical Trials in Oncology (1) Shanghai Junshi Bioscience Co., Ltd. (1) University of Florida (1) Mannkind (1) Sun Yat-sen University (1) Advenchen Laboratories (1) Guangzhou Virotech Pharmaceutical (1)
FLT4 (22) FLT1 (19) PDGFRB (10) KIT (6) PDGFRA (4) MET (3) PDCD1 (3) CD274 (2) AURKB (1) FGFR1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.